GlaxoSmithKline outlines plans ahead of Pfizer spinoff

GlaxoSmithKline outlined its plans to prepare itself for its spinoff consumer healthcare unit with Pfizer during its fourth-quarter results presentation Feb. 5, FirstWord Pharma reported. 

The drugmaker said it has started a two-year program to prepare for the spinoff company to launch in 2022. The new company will focus on immune system drugs, genetics and new technologies and could become the largest seller of such drugstore basics as Advil and Tums. 

The company plans to focus on research and development and new product launches this year and is considering divesting some  non-core assets, such as its prescription dermatology business. It is trying to save $910 million by 2022. 

GlaxoSmithKline also plans to cut as many as 720 jobs from its vaccine unit in Belgium, according to FirstWord Pharma. 

Read the full article here

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars